Elicit: TAF Activation and Tenofovir Distribution in HIV-1 Cells

TAF Activation and Tenofovir Distribution in HIV-1 Cells

Tenofovir alafenamide (TAF) intracellular activation and tenofovir distribution to HIV-1 infected cells

TAF is activated intracellularly by cathepsin A to produce tenofovir diphosphate at 4- to 25-fold higher concentrations than TDF in peripheral blood mononuclear cells, with preferential distribution to lymphatic tissues and HIV-susceptible cells including CD4+ T cells, epithelial cells, and fibroblasts.

Abstract

Tenofovir alafenamide undergoes intracellular activation primarily through the lysosomal protease cathepsin A, which cleaves TAF to form intermediates that ultimately convert to the active metabolite tenofovir diphosphate (TFV-DP). Liver carboxylesterase 1 provides an alternative hepatic activation pathway. This intracellular activation mechanism enables TAF to achieve 4- to 25-fold higher TFV-DP concentrations in peripheral blood mononuclear cells compared to tenofovir disoproxil fumarate (TDF), while reducing systemic tenofovir exposure by 86-97%. TAF demonstrates preferential distribution to lymphatic tissues and accumulates in epithelial cells and fibroblasts of the female reproductive tract at 10- to 100-fold higher concentrations than in CD4+ T cells, with these cells releasing antiretroviral activity over multiple days to protect CD4+ T cells.

The enhanced intracellular TFV-DP loading translates to superior antiviral activity, with TAF demonstrating >600-fold greater potency than parent tenofovir in CD4+ T cells and a 3.5-fold higher resistance barrier than TDF. In viral breakthrough assays at physiologically relevant concentrations, TAF inhibited 40 of 42 K65R-containing isolates while TDF inhibited only 32 of 42, and TAF prevented breakthrough in 65 of 68 isolates with thymidine analog-associated mutations compared to 53 of 68 for TDF. The covalent hepatitis C protease inhibitors telaprevir and boceprevir potently inhibit cathepsin A-mediated TAF activation (IC50 0.16-0.27 μM), reducing anti-HIV activity 3- to 21-fold, while medroxyprogesterone acetate differentially suppresses TAF activity in genital versus blood CD4+ T cells. These findings support TAF’s clinical efficacy at lower doses than TDF with improved safety profiles and activity against resistant HIV-1 strains.

Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

Records from Elicit search

Papers screened using:

Results

Characteristics of Included Studies

The review included 10 studies published between 2013 and 2023 examining TAF intracellular activation and tenofovir distribution to HIV-1 infected cells.

Study Full text retrieved? Study type Primary focus Cell types studied
Rujuta A. Bam et al., 2014 No Primary study CatA levels and intracellular metabolism across diverse donors Primary CD4+ T-lymphocytes and monocyte-derived macrophages
C. Callebaut et al., 2015 Yes Primary study In vitro virology profile of TAF MT-2 and MT-4 cell lines, primary human PBMCs, CD4+ T lymphocytes
G. Birkuš et al., 2015 Yes Primary study Intracellular activation mechanisms and enzyme involvement HEK293T cells, HeLa cells, primary human CD4+ T lymphocytes
N. Margot et al., 2020 Yes Primary study Antiviral activity against TAM-containing HIV-1 MT-2 cells
N. Margot et al., 2015 Yes Primary study In vitro resistance characterization MT-2 cells, PBMCs
N. Margot et al., 2016 No Primary study Resistance barrier driven by higher TFV-DP loading HIV-1 infected cells
S. Cox et al., 2023 Yes Primary study Antiviral activity against K65R-containing isolates Patient-derived HIV-1 isolates, MT-2 cells, HEK293T cells
Zheng Shen et al., 2017 Yes Primary study Hormonal contraceptive effects on TAF activity Primary CD4+ T cells from blood and female reproductive tract tissues
Zheng Shen et al., 2019 Yes Primary study TAF accumulation and release from reproductive tract cells Primary epithelial cells and fibroblasts from female reproductive tract
P. Ruane et al., 2013 Yes Phase 1b clinical trial Antiviral activity, safety, and pharmacokinetics of TAF monotherapy HIV-1-positive adults

Studies employed diverse experimental approaches including enzyme assays, drug uptake studies, resistance selection experiments, viral breakthrough assays, and clinical pharmacokinetic measurements. Experimental durations ranged from 24-hour incubations to multi-week resistance selection experiments lasting up to 74 days and a 10-day clinical monotherapy trial. Technical methods included HPLC, liquid chromatography with tandem mass spectrometry, luciferase-based viability readouts, and RT-PCR for gene expression analysis.

TAF Activation Mechanisms

Enzymatic Pathways

TAF undergoes intracellular activation primarily through the lysosomal protease cathepsin A (CatA). The activation occurs in the lysosomal compartment, where CatA cleaves the carboxyester bond in TAF to form a metastable metabolite. This metabolite then converts to TFV-Ala, which spontaneously converts to TFV due to the acidic pH in lysosomes. Subsequently, TFV undergoes two sequential phosphorylation reactions to form the active metabolite TFV-DP.

Alternative Activation Pathways

Liver carboxylesterase 1 (Ces1) represents an alternative pathway for TAF activation.

Intracellular Drug Concentrations and Distribution

Comparative TFV-DP Levels

TAF achieves substantially higher intracellular concentrations of the active metabolite TFV-DP compared to its predecessor TDF. The fold increases in TFV-DP concentrations varied across studies and doses:

Study Cell type Fold increase vs TDF TAF dose Time point
C. Callebaut et al., 2015 PBMCs 5-fold Not specified Not specified
N. Margot et al., 2020 PBMCs >4-fold Not specified Not specified
N. Margot et al., 2015 PBMCs 5- to 7-fold Phase 1 study Not specified
S. Cox et al., 2023 PBMCs >4-fold 4× TDF equivalent Not specified
P. Ruane et al., 2013 PBMCs 7-fold (25 mg)
25-fold (40 mg)		 25 mg and 40 mg Day 21

Tissue-Specific Distribution

TAF demonstrates preferential distribution to lymphatic tissues and HIV-susceptible cells. In the female reproductive tract, epithelial cells and fibroblasts accumulate TFV-DP at substantially higher levels than CD4+ T cells.

Donor Variability

Levels of CatA and intracellular TAF metabolites differed minimally in CD4+ T cells and monocyte-derived macrophages among 13 demographically diverse donors tested.

Comparison with Tenofovir Disoproxil Fumarate

Potency and Activation Efficiency

TAF demonstrated markedly superior potency compared to parent TFV and the alternative prodrug TDF across multiple dimensions:

Parameter TAF advantage Source
Potency vs TFV in CD4+ T cells >600-fold more potent Rujuta A. Bam et al., 2014
Potency vs TFV in macrophages 80-fold more potent Rujuta A. Bam et al., 2014
Effective concentration ~300-fold lower than TFV Zheng Shen et al., 2017; 2019
Enhanced in vitro antiviral activity >600-fold vs TFV G. Birkuš et al., 2015

Mechanistic Differences

TAF and TDF employ fundamentally different activation pathways. TAF is converted intracellularly by CatA or Ces1, whereas TDF is quickly metabolized to TFV by gut and serum esterases.

Pharmacokinetic Profiles

Study TAF dose Plasma TFV reduction Intracellular TFV-DP increase
G. Birkuš et al., 2015 Not specified Lower systemic levels Higher concentrations in PBMCs
N. Margot et al., 2015 25 mg 86% reduction 5- to 7-fold increase
P. Ruane et al., 2013 8 mg 97% lower Not specified
P. Ruane et al., 2013 25 mg 86% lower 7-fold increase
P. Ruane et al., 2013 40 mg 79% lower 25-fold increase

Activity Against Resistant HIV-1 Strains

TAF activity was evaluated against multiple resistance mutations, with K65R and thymidine analog-associated mutations receiving particular attention.

Mutation type TAF susceptibility change Study
K65R alone 6.5-fold reduced N. Margot et al., 2015
K65R + other RT mutations 1.2- to 27.6-fold reduced S. Cox et al., 2023
Multiple TAMs Variable reduction N. Margot et al., 2020

Resistance Barrier Comparison

TAF demonstrated a substantially higher resistance barrier than TDF across multiple experimental systems.

Factors Affecting TAF Activation and Distribution

Drug Interactions

TAF demonstrated additive to synergistic interactions when combined with antiretroviral drugs from different classes including NRTIs, NNRTIs, integrase strand transfer inhibitors, and protease inhibitors.

Hormonal Contraceptive Effects

Medroxyprogesterone acetate (MPA) exhibited differential effects on TAF and TFV activity depending on cell type.

Cellular and Environmental Factors

Host factors including cathepsin A expression levels play a critical role in TAF activation. Ces1 expression is particularly important for hepatic TAF metabolism.

Clinical Implications

Dosing and Efficacy

TAF demonstrates potent antiviral activity at lower doses than TDF, which may translate into greater antiviral efficacy, a higher barrier to resistance, and an improved safety profile.

Safety Considerations

The reduced systemic TFV exposure with TAF compared to TDF has important safety implications.

Monitoring and Resistance Testing

Higher resistance cutoffs should be applied for TAF compared to TDF in genotypic and phenotypic resistance algorithms.

Knowledge Gaps and Future Directions

Clinical validation of TAF’s higher resistance threshold remains limited due to ethical concerns regarding resistance induction studies. Further research is needed on TAF distribution and activation in genital tissues, particularly under conditions of inflammation and sexually-transmitted infections.